Inloggen

Login
 
Wachtwoord vergeten?

Aandeel Celyad BRU:CYAD, BE0974260896

  • 5,880 16 apr 2021 17:35
  • -0,040 (-0,68%) Dagrange 5,850 - 6,020
  • 38.353 Gem. (3M) 29,7K

Celyad 2021

348 Posts
Pagina: «« 1 ... 13 14 15 16 17 18 | Laatste | Omlaag ↓
  1. forum rang 6 egeltjemetstekel 15 april 2021 19:24
    simplywall.st/stocks/be/pharmaceutica...

    Here's Why Celyad Oncology (EBR:CYAD) Must Use Its Cash Wisely
    BySimply Wall StPublishedApril 15, 2021
    ENXTBR:CYAD
    We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

    So, the natural question for Celyad Oncology (EBR:CYAD) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

    Check out our latest analysis for Celyad Oncology

    Does Celyad Oncology Have A Long Cash Runway?
    You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. Celyad Oncology has such a small amount of debt that we'll set it aside, and focus on the €17m in cash it held at December 2020. Importantly, its cash burn was €28m over the trailing twelve months. So it had a cash runway of approximately 7 months from December 2020. That's quite a short cash runway, indicating the company must either reduce its annual cash burn or replenish its cash. Depicted below, you can see how its cash holdings have changed over time.

    debt-equity-history-analysis
    ENXTBR:CYAD Debt to Equity History April 15th 2021
    How Is Celyad Oncology's Cash Burn Changing Over Time?
    Although Celyad Oncology had revenue of €5.0k in the last twelve months, its operating revenue was only €5.0k in that time period. Given how low that operating leverage is, we think it's too early to put much weight on the revenue growth, so we'll focus on how the cash burn is changing, instead. It's possible that the 2.9% reduction in cash burn over the last year is evidence of management tightening their belts as cash reserves deplete. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

    How Easily Can Celyad Oncology Raise Cash?
    While Celyad Oncology is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

    Since it has a market capitalisation of €88m, Celyad Oncology's €28m in cash burn equates to about 32% of its market value. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution.

    Is Celyad Oncology's Cash Burn A Worry?
    On this analysis of Celyad Oncology's cash burn, we think its cash burn reduction was reassuring, while its cash runway has us a bit worried. After looking at that range of measures, we think shareholders should be extremely attentive to how the company is using its cash, as the cash burn makes us uncomfortable. On another note, Celyad Oncology has 5 warning signs (and 3 which make us uncomfortable) we think you should know about.

    Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

    Promoted
    If you’re looking to trade Celyad Oncology, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.


    This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
    *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    Discounted cash flow calculation for every stock
    Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

    Simply Wall St
    Simply Wall St is a financial technology startup focused on providing unbiased, high-quality research coverage on every listed company in the world. Our research team consists of equity analysts with a public, market-beating track record. Learn more about the team behind Simply Wall St.

  2. Garre 15 april 2021 19:57
    een heleboel tekst maar staat niks bijzonders, dit is gewoon een advies wat we allemaal weten, het bedrijf levert nog niks op en houd de kosten, de 40 miljoen die men nog kan aanboren houd het bedrijf nog zeker jaren overeind, ook de Belgische overheid blijft misschien wel investeren.
    Ik kan er niks bijzonders uithalen, wie ziet er wat anders in dit artikel?
    Dat we laag staan en blijven is niks aan, maar als je de rit omhoog dan weer zult missen is ook heel zuur. Komende weken/maanden hopelijk meer top nieuws.
  3. COMPLEET 15 april 2021 21:35
    Komt allemaal goed ; mijn voorspellingen Mithra zijn volkomen ingewilligd. Bekijk maar eens forum en mijn voorspellngen. Ik heb 3700 stuks Mithra en 10000 stuks celyad en 10000 stuks bone therapeutics. Dit worden alle 3 toppertjes. Ook al werkt mijn partner binnen Novartis - nog nooit gedacht om me te laten verleiden tot zo'n aandeel. Hiermee wil ik zeggen dat mijn onderzoek en info wel 100 pct klopt.
    Tot binnenkort ; nu nog even focus op Mithra.
  4. Krustie101 17 april 2021 08:34
    quote:

    COMPLEET schreef op 15 april 2021 21:35:


    Komt allemaal goed ; mijn voorspellingen Mithra zijn volkomen ingewilligd. Bekijk maar eens forum en mijn voorspellngen. Ik heb 3700 stuks Mithra en 10000 stuks celyad en 10000 stuks bone therapeutics. Dit worden alle 3 toppertjes. Ook al werkt mijn partner binnen Novartis - nog nooit gedacht om me te laten verleiden tot zo'n aandeel. Hiermee wil ik zeggen dat mijn onderzoek en info wel 100 pct klopt.
    Tot binnenkort ; nu nog even focus op Mithra.


    Niet helemaal.

    Deze is niet uitgekomen:
    www.iex.nl/Forum/Post/13365869.aspx

    Over de meest gewaagde heb ik ook mijn twijfels:
    www.iex.nl/Forum/Post/13342020.aspx
  5. BXL1070 18 april 2021 19:22
    quote:

    egeltjemetstekel schreef op 12 april 2021 11:30:


    bisouv.com/world/4403582/t-cell-immun...

    T-cell immunotherapy market is projected to grow at an annualized rate of 12.2%, claims Roots Analysis

    April 12, 2021
    Driven by high success rates in clinical trials and the potential to confer sustained periods of disease remission, T-cell therapies have received significant financial support, with approved products poised to soon achieve blockbuster status


    Dank voor deze bijdrage!

    Helaas zitten we ondertussen wel aan een 52 weken laagtepunt. Ik ga het erop wagen om nog wat voorzichtig bij te kopen. Laten we toch hopen in 2021 nog terug een stijgende lijn te zien onder invloed van goed nieuws omtrent de lopende studies.
348 Posts
Pagina: «« 1 ... 13 14 15 16 17 18 | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Celyad Meer »

Koers 5,880   Verschil -0,04 (-0,68%)
Laag 5,850   Volume 38.353
Hoog 6,020   Gem. Volume 29.662
16 apr 2021 17:35
label premium

Celyad: private plaatsing

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium
 

Trending

    Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
    #/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare